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23 1. Introduction
24 Infection control is a diverse area of healthcare which evolved most rapidly in the middle of the last 
25 century, mainly to the benefit of Homo sapiens.  In the modern consciousness it is not an area 
26 associated with dyes.  Consider the following two situations.
27 Contemporary view
28 In 2017, a businesswoman attending her GP with suspected tonsillitis is expecting to be prescribed 
29 an antibiotic, to have the prescription filled at a local pharmacy and then to begin the self-
30 administered therapy at home.  The GP, having examined the patient’s neck glands externally and 
31 the back of her throat with a light and a tongue suppressor, suspects bacterial infection and 
32 prescribes the penicillin derivative, amoxicillin.
33 The woman has the prescription filled at the pharmacy and is supplied with a seven-day course of 
34 capsules.  These are taken for the first three days, by which time she no longer has a sore throat or 
35 swollen glands and, having many other important matters to deal with at the office, forgets about 
36 the situation with her throat and so discontinues the course.
37
38 Pre-antibiotic view
39 In 1932, a Sheffield (UK) steelworks’ foreman presents at a local hospital with a burn wound to his 
40 left forearm.  The wound is cleaned and then dressed with a greasy formulation containing the 
41 bright yellow dye acriflavine.  The foreman returns to work straight from the hospital.  As the wound 
42 eventually heals, there is no follow-up.
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344 The first scenario described is not untypical.  However, in terms of the fight against antimicrobial 
45 drug resistance (AMR) the discontinuation of therapy is a cause for concern which has, 
46 unfortunately, been with us since the general availability of antibiotics following the Second World 
47 War.  Moreover, it is only one of a number of causes for concern.
48 The second scenario, again, does not represent an unusual occurrence.  Because it is set in the pre-
49 antibiotic era, the conventional approach to local infection would often involve the use of an 
50 antimicrobial dye.  Methylene blue had been used in malaria (though probably not in Sheffield) for 
51 over forty years by this time; “Flavine therapy” - usually employing acriflavine, proflavine or brilliant 
52 green - had saved countless lives in the base hospitals in France during World War I; acriflavine, 
53 brilliant green and crystal (gentian) violet continued to be used in healthcare in controlling infection.  
54 Furthermore, occurrences in the industrial screening of derivatives of these dyes would shortly usher 
55 in the above-mentioned antibiotic era via the azoic dye Prontosil and the consequent sulphonamide 
56 ‘Gold Rush’ of the late 1930s [1].
57 While both situations describe effective infection control, there are obviously potential downsides in 
58 each case.  The former describes potentially sub-lethal dosing, which is accepted as bad practice, 
59 potentially leading to drug resistance development among the patient’s internal microbiota [2].  The 
60 latter approach was not always successful and, clearly, produced staining of the wound and, 
61 presumably, the surrounding tissue.  The application of acriflavine also required medical assistance.
62 Of the two approaches, antibiotic therapy has enjoyed generally unchallenged use since the mid-
63 1940s rapidly eclipsing the dyes which had been in widespread use in infection control for the 
64 previous 30 years.
65
66 1.1. Antimicrobial resistance
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467 There can be little doubt that straightforward dosing using antibiotic capsules or suspensions has 
68 allowed simple control of a high percentage of bacterial infections and that this control has required 
69 very little in terms of medical supervision.  Such end-user independence in the face of the 
70 pathogenic threat is logically highly desirable, and an aspirational hallmark of highly evolved, 
71 affluent civilisation.  A similar situation pertains to the food animal stock required by such a society.
72 However, such has been our over- and mis-use of antibiotics – against self-limiting or non-bacterial 
73 infection in humans, or as growth-promoters in livestock, for example – that bacterial drug 
74 resistance has now attained dangerous levels and without a productive pipeline of new antibiotics is 
75 now cited as a threat to civilisation in the same breath as global warming and international terrorism 
76 [3-5].
77 In terms of modern alternatives to antibiotics, the main coverage is given to vaccines, 
78 bacteriophages and other biological approaches [6].  The use of dyes in this respect seems to be 
79 promoted only by those working in the field of photoantimicrobials.
80
81 2. Dyes and photoantimicrobials
82 But why not use dyes in infection control?  As noted above, flavine therapy was not always 
83 successful, but the modern, targeted use of such - or related - dyes in conjunction with targeted light 
84 provides highly effective microbial killing via the intermediacy of reactive oxygen species (Figure 1), 
85 whether of penicillin-sensitive streptococci, meticillin-resistant Staphylococcus aureus or ESBL-
86 expressing Klebsiella pneumoniae [7].  Given that several articles have appeared recently reporting 
87 the apparent imperviousness of strains of the latter bacterium against any antibiotic [8], the 
88 photoantimicrobial approach (Figure 1) offers considerable benefit.
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590 [Figure 1]
91
92 So why aren’t dyes – and particularly photoantimicrobial examples – being introduced to support 
93 the conservation of our essential antibiotic arsenal?
94 The answer may lie a considerable way back, in the early part of the last century.
95 The purpose of flavine therapy was to stain selectively and thus inactivate the microbes present in 
96 the target tissue.  The application of sufficient quantities of dye to facilitate this effect inevitably led 
97 to staining of the tissue surrounding the target area.  Were this process to be carried out with a 
98 modern, colourless biocide, such as chlorhexidine, such staining - although present - would, of 
99 course, be invisible.  The comparison of dye and biocide action is covered below.  Tissue staining, or 
100 discolouration, is unpopular with patients, especially when visible in public, or when garments 
101 become stained.  In the period before sulphonamide introduction, when brilliant green was a 
102 common antibacterial, often used in obstetrics, the famous medic L.P. Garrod wrote of complaints 
103 from patients concerning the dye: “It is objected to on account of its staining propensities; whether 
104 stained linen or death from septicaemia is the greater evil is a question which seems to admit of only 
105 one answer.” [9]. This comment was made in the “pre-antibiotic” period, so often referenced by 
106 today’s media.
107 It is also well-known that Alexander Fleming was disparaging about the use of dyes in infectious 
108 disease.  He wrote in a 1917 Lancet article that “… the theoretical basis for the use of dyes [as 
109 antimicrobials] is thoroughly unsound” [10].  It should be noted that Fleming’s argument was based 
110 on in vitro laboratory work, rather than Browning’s successful clinical use of acriflavine and brilliant 
111 green.
112 In order to minimise the staining problem, the Australian chemist Adrien Albert carried out an 
113 enormous amount of acridine synthesis during the 1930s and 40s, developing possibly the first 
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6114 properly organised molecular structure-activity relationships and delivering, among others, the non-
115 staining antibacterial drugs aminacrine and diflavine (9-amino and 2,6-diaminoacridine, 
116 respectively), as well as the (yellow) antimalarial mepacrine [11].
117
118 2.1. Methylene blue and malaria
119 It is of little surprise that the conventional drugs derived from medical dyes in the mid-20th Century – 
120 such as the sulphonamides or chloroquine - were colourless but, as our supply of effective, 
121 colourless contemporary drugs dwindles, can we really use a distaste for staining as a reason not to 
122 use effective, coloured alternatives?  And there is a modern, 21st Century precedent.
123 Drug resistance is not a new phenomenon.  Monotherapy of malaria produced significant levels of 
124 chloroquine-resistant parasites (plasmodia) by the early 1960s and in sub-Saharan Africa by the 
125 following decade [12].  This was, and is, a scourge, particularly among the young.  As a response, 
126 methylene blue was introduced – as a conventional antimalarial, rather than a photoantimicrobial - 
127 for the treatment of juvenile malaria in Burkina Faso in 2005 [13]. This represents the systemic 
128 administration of an intensely blue substance which leads to colouring of the urine and stool, as well 
129 as clothing and intimate apparel.  Furthermore, the population being treated belongs to highly 
130 structured and regulated tribal systems where a child producing strangely coloured waste might 
131 otherwise be ostracised.  This has been avoided by extended discussions with tribal elders prior to 
132 the commencement of therapy [14].
133 Such an approach might be seen by those in affluent societies with easy access to high-tech 
134 healthcare to be a retrograde step.  It is not.  Rather it represents the logical use of an effective, 
135 relatively inexpensive drug, taking into account an insignificant side-effect, in the face of widespread 
136 treatment failures with conventional therapeutics.
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7137 The argument for the use of methylene blue - or another of the approved medical dyes which are 
138 also photosensitisers (e.g. toluidine blue or crystal violet) - as a photoantimicrobial in modern 
139 healthcare is very similar, save for the fact that treatment would be localised, rather than systemic.  
140 There is an understandable assumption that treatment using this approach must be limited to 
141 topical therapy.  This is not the case since, given access to endoscopic techniques and fibre optic 
142 technology, most regions of the body are accessible, both to the local delivery of a 
143 photoantimicrobial and also of light.
144
145
146 2.2. Advantages of the photoantimicrobial approach
147 In addition, one of the major strengths of photoantimicrobials is their broad-spectrum, truly 
148 antimicrobial action (i.e. against bacteria, viruses, fungi and protozoa), regardless of conventional 
149 resistance status. As noted, 21st Century resistance, for example to antibacterial drugs, is increasingly 
150 difficult – and expensive - to treat with other conventional agents (Figure 2).
151
152 [Figure 2]
153
154 3. Photoantimicrobial use in the clinic
155 Thus we have a combination of highly –effective and rapid antimicrobial action which works best 
156 against a localised infection, regardless of microbial type. How might this be used positively in 
157 modern infection control?
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8158 Tonsillitis is a very common illness which may have a bacterial or viral aetiology.  Its treatment is 
159 often given as a good example of bad practice, viz. the prescription amoxicillin (typically, as noted 
160 above) by physicians before this aetiology is established, often leading to pointless – and ultimately 
161 dangerous – antibiotic exposure of the patient’s microbiota.  The application of a 
162 photoantimicrobial, such as methylene blue, to the tonsils, followed by a short illumination – about 
163 30 seconds – with a light probe should provide sufficient bacterial kill locally, with no effect further 
164 on the alimentary tract, or systemically.  Any photoantimicrobial swallowed during the procedure 
165 would have no effect, as only the illuminated area would be activated. Such a situation can be 
166 assumed for most local infections, in each case allowing the removal of conventional antimicrobials 
167 from the treatment protocol, and this would be possible regardless of the resistance status of the 
168 infecting microbes.
169 Photoantimicrobial application in this way could be of major impact if the infection is already 
170 difficult to treat using conventional agents – for example in drug-resistant cases or where a drug 
171 cocktail is required, as in pulmonary tuberculosis [18,19].  Other presentations include diabetic foot 
172 ulcers, which have been shown to be responsive to this approach (Figure 3) in cases where the 
173 standard option is amputation [20].  Even without the spectre of infection by multiple-drug resistant 
174 bacteria, this would be of enormous benefit to the patients involved, as well as offering enormous 
175 cost savings in terms of surgical procedures, rehabilitation and onward care.
176
177 [Figure 3]
178
179 The same approach is currently in use in patient decolonisation in Canada.  The effect of light-
180 activated methylene blue against meticillin-resistant Staphylococcus aureus (MRSA) is well 
181 established [21] and this has been applied to the decolonisation of elective surgical patients in a 
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9182 Vancouver hospital, with subsequent decreases reported in post-op MRSA infection rates [22].  In 
183 such cases photoantimicrobials conserve the standard prophylactic drugs normally employed in 
184 addition to those required in an anti-MRSA capacity, post-op.  There is no reason why the 
185 prophylactic route cannot be applied to ‘lesser’ infections which commonly precede highly 
186 dangerous ones, such as pneumonia, meningitis and sepsis, thus blocking the progression from, for 
187 example, tonsillitis, otitis media or sinusitis to these high mortality-associated diseases.
188
189 3.1. Using directed light for therapeutic activation.
190 Clearly, effective photoantimicrobial action is only achieved with an efficient light source – i.e. of the 
191 correct wavelength range and of sufficient power output – and this may be another perceived hurdle 
192 to clinical acceptance.
193 An undoubted strength, in theory, of modern antibiotic use is that in most cases the drugs are self-
194 administered, usually via the oral route.  Ideally, the involvement of the clinician is solely in 
195 examining the sufferer and prescribing the requisite drug.
196 The addition of light activation to the therapeutic equation may require medical supervision or 
197 operation. There is, of course, a parallel - and absolutely routine - situation in many dermatology 
198 departments in the treatment of psoriasis, vitiligo and other skin disorders with psoralens, activated 
199 by ultraviolet-A radiation (PUVA therapy).  The dangers of UV-A are well documented, while there 
200 are none with red light [23], but the fact remains that the proper direction of illumination, as well as 
201 providing the correct light fluence (i.e. how much, for how long), might require trained personnel.  
202 This would certainly be the case for procedures requiring administration and optical fibre use inside 
203 the body.
204 Should the requirement for trained medical staff – typically general practice nurses are envisaged – 
205 be a sufficient reason to discount the approach?  Again, it is emphasised that photoantimicrobials 
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206 are effective against resistant bacteria, so a one-off treatment – e.g. again for an Ear, Nose & 
207 Throat/Upper Respiratory Tract infection - would be sufficient, regardless of resistance status.  
208 Surely the initial expense in training and equipment would far outweigh both the multiple 
209 treatments required for resistant disease and the deleterious effects on patients’ microbiota?  
210 Obviously, other alternative therapies, such as vaccines and bacteriophages would also require 
211 medical administration.
212
213 3.2. Photoantimicrobials vs. biocidal agents
214 What is the difference between a photoantimicrobial agent and a biocide?  Aside from the 
215 requirement for light activation, both types have multiple sites of action.  However, for biocides, 
216 such as bisguanides (e.g. chlorhexidine gluconate) or quaternary ammonium salts (e.g. benzalkonium 
217 chloride) this is mainly due to the extremely high concentration in which they are administered – 
218 usually at tens or hundreds of times the minimum inhibitory concentration for the target organism.  
219 While this is acceptable externally in terms of host toxicity, such concentration at internal sites could 
220 be dangerous [24].  As can be seen from Figure 4, cationic photoantimicrobials are active at much 
221 lower concentrations on illumination, and these concentrations fall far below safe levels for known 
222 vital stains, such as methylene blue, when used systemically – usually in 1 % w/v solution, equivalent 
223 to 32000 mol L-1.
224 [Figure 4]
225
226 4. Conclusion and ways forward
227 Various clinicians in the Pacific North-West and in Brazil are using methylene blue for local 
228 photodisinfection, for the most part in dental applications.  This successful approach allows the 
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11
229 conservation of antibiotics and should be both a clear demonstration of the utility of the approach 
230 and a strong argument for its wider introduction, both in local disinfection and in prophylaxis.  The 
231 approach is particularly relevant in the current – and likely lasting - period of widespread decreasing 
232 antibiotic efficacy and it now requires active participation from those with influence in both the 
233 healthcare and pharmaceutical/biotech lobbies in order to realise this.  In addition, the introduction 
234 of protocols requiring the administration of photoantimicrobials – and other, non-conventional 
235 approaches - must engender a new way of thinking about infection control.  As a modern society this 
236 should not be beyond possibility, and we have, of course, done it before.
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298 Figure legends
299
300 Figure 1. Adapted Jablonski diagram for photoantimicrobial action.  Key: S0 – singlet electronic 
301 ground state of photoantimicrobial molecule; S1 – singlet excited state; T1 – triplet excited state; A – 
302 photon absorption; F- relaxation by fluorescence; ISC – intersystem crossing; P – phosphorescence; 
303 3O2 – ground-state, triplet oxygen.  Reactive oxygen species: 1O2 – excited-state, singlet oxygen; O2- - 
304 superoxide anion; HO. – hydroxyl radical; H2O2 – hydrogen peroxide.
305
306 Figure 2.  Minimum bactericidal or fungicidal concentrations (MBC or MFC, respectively,  in 
307 micromoles) of standard antimicrobial agents  and photoantimicrobials against: (a) Pseudomonas 
308 aeruginosa, (b) methicillin-resistant Staphylococcus aureus, (c) Propionibacterium acnes and (d) 
309 Candida albicans in vitro.  Light activation 660 nm LED array, light fluence = 6 J cm-2.  
310 Photoantimicrobial activity is shown by pale grey bars, black bars indicate dark activity, maximum 
311 concentration tested = 100 M.  Drug key: Levo – levofloxacin; fluclox – flucloxacillin; vanc – 
312 vancomycin; BPO – benzoyl peroxide; flucon – fluconazole.  Exemplar photoantimicrobial structures 
313 are given above [15-17].
314
315 Figure 3.  Successful photoantimicrobial treatment of the diabetic foot. (a) Initial presentation; (b) 90 
316 days’ post-treatment with methylene blue/toluidine blue/light (Courtesy of Dr J.P. Tardivo, Fundação 
317 Medicina ABC, Santo André, SP, Brazil).
318
319 Figure 4.  Minimum bactericidal concentrations (MBC, in micromoles) of standard biocidal agents 
320 (CTAB = cetyl trimethylammonium bromide) and photoantimicrobials against Staphylococcus aureus 
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321 (pale grey bars) and Escherichia coli (dark grey bars) in vitro. Light activation 660 nm LED array, light 
322 fluence = 6 J cm-2.  Black bars indicate dark activity, maximum concentration tested = 100 M.  
323 Photosensitiser structures are provided in Figure 2, above [15-17].
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